Detalles de la búsqueda
1.
Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38657084
2.
An introduction to the Marburg virus vaccine consortium, MARVAC.
PLoS Pathog
; 18(10): e1010805, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36227853
3.
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
J Infect Dis
; 226(4): 595-607, 2022 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32939546
4.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015777
5.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis
; 223(7): 1171-1182, 2021 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821493
6.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med
; 18(10): e1003813, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34714820
7.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
J Infect Dis
; 220(1): 57-67, 2019 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796816
8.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
J Infect Dis
; 220(1): 46-56, 2019 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796818
9.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
JAMA
; 315(15): 1610-23, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27092831
10.
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Hum Vaccin Immunother
; 20(1): 2327747, 2024 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523332
11.
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Vaccines (Basel)
; 12(2)2024 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400193
12.
Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection.
J Exp Med
; 204(5): 979-85, 2007 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-17452519
13.
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.
Cell Rep
; 42(9): 113101, 2023 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691146
14.
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Front Immunol
; 14: 1215302, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37727795
15.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine
; 91: 104562, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099841
16.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Vaccine
; 41(50): 7573-7580, 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981473
17.
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Lancet Infect Dis
; 23(3): 352-360, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273490
18.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Lancet Glob Health
; 11(11): e1743-e1752, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37858585
19.
A novel type of macrothrombocytopenia associated with a defect in α2,3-sialylation.
Am J Pathol
; 179(4): 1969-77, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21864493
20.
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.
JAMA
; 317(10): 1075-1077, 2017 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28291882